Introduction
============

Lung cancer is the leading cause of cancer-associated mortality worldwide, and adenocarcinoma (ADC) is the most common histological type of lung cancer ([@b1-ol-0-0-4154]). Among males, ADC was the most common type in the United States (31%), Canada (31%), Sweden (30%) and Australia (29%). Among females, ADC made up the greatest proportion of lung cancers, ranging between 38% in the United States and 69% in Japan ([@b2-ol-0-0-4154]).

Lung ADC is generally heterogeneous, consisting of cells of two or more histological subtypes. In total, 80--90% of surgically resected lung ADCs consist of a mixture of histopathological subtypes ([@b3-ol-0-0-4154]). In 2011, the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS) and European Respiratory Society (ERS) proposed a novel international multidisciplinary classification system for lung ADC, which classifies patients according to the predominant structural morphology observed in ADC ([@b4-ol-0-0-4154]). Regarding early-stage invasive adenocarcinomas, the lepidic predominant subtype is associated with better disease free survival (DFS) rates, ranging between 75--85% at 5 years. The acinar and papillary subtypes have intermediate prognosis, with 5-year DFS ranging between 50--70%. The micropapillary and solid predominant subtypes have the poorest prognoses, with 5-year survival rates of 30--40% ([@b5-ol-0-0-4154]--[@b9-ol-0-0-4154]). During the past 10 years, targeting the epidermal growth factor receptor (EGFR) pathway has become the mainstream of treatment for advanced lung ADC. The identification of the association between histology and EGFR status becomes clinically relevant when choosing which patients may receive properly targeted therapies. Fluorine-18 fluorodeoxyglucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) is a metabolic imaging technique that accurately detects the increased trapping of glucose in cancer cells. High FDG uptake may be associated with a poor prognosis of lung cancer ([@b10-ol-0-0-4154]).

Increasing evidence demonstrates that the histopathological subtype of ADC is closely associated with EGFR mutations and ^18^F-FDG uptake, which may be identified using PET-CT ([@b11-ol-0-0-4154]--[@b13-ol-0-0-4154]). However, to the best of our knowledge, the association between lung ADC histopathological subtypes, EGFR mutations and ^18^F-FDG uptake remains unclear. Therefore, the present study retrospectively reviewed and reclassified surgically resected lung ADC according to the novel IASLC/ATS/ERS classification, in order to elucidate the association between lung ADC subtype, EGFR mutation status and ^18^F-FDG uptake. In addition, the association between the EGFR mutations and clinicopathological characteristics of the patients was investigated to determine independent predictors for EGFR mutations.

Patients and methods
====================

### Patients

The protocol of the present study was reviewed and approved by the Institutional Review Board of China-Japan Friendship Hospital (Beijing, China). A total of 97 patients with lung ADC who underwent ^18^F-FDG PET-CT prior to surgical resection between January 2013 and September 2014 were enrolled in the current retrospective study. The resected tumor specimens were pathologically confirmed as primary lung ADC, according to the 2004 World Health Organization (WHO) classification ([@b14-ol-0-0-4154]). The clinical data of the patients, including age, gender, smoking history, pre-operative serum carcinoembryonic antigen (CEA) level and tumor site, were obtained and are summarized in [Table I](#tI-ol-0-0-4154){ref-type="table"}.

### Integrated ^18^F-FDG PET-CT

^18^F-FDG PET-CT was performed using an integrated PET-CT scanner (GE Discovery ST; GE Healthcare Life Sciences, Chalfont, UK). All patients with a pre-scan glucose level of \>200 mg/dl fasted for 6 h prior to the PET/CT scan, followed by intravenous administration of 7.4 MBq/kg ^18^F-FDG (Atom Hi-Tech Co., Ltd., Beijing, China). PET scans between the skull base and mid-thigh levels were performed 1 h after ^18^F-FDG injection. Concomitant CT data were used for attenuation correction of PET images and anatomical localization of PET abnormalities. All PET-CT images were evaluated and reviewed by two experienced nuclear medicine physicians from the China-Japan Friendship Hospital. The region of interest (ROI) was manually drawn around the primary tumor and the activity concentration of ^18^F-FDG in the ROI was determined and expressed as the standardized uptake value (SUV). The SUV was adjusted for the injected dose of ^18^F-FDG and the body weight of the patient using the standard software tools provided with the PET-CT scanner. In order to minimize variation according to the size of the ROIs and assure reproducibility, the maximum SUV (SUVmax) was defined as the peak SUV of the pixel with the highest counts in the sequential transaxial scans through the ROI.

### Histopathological evaluation

Hematoxylin and eosin-stained slides for the lung ADC of each patient (mean, 4 slides/patient; range, 1--13 slides/patient) were assessed in a blinded and independent manner for the histopathological subtype of lung ADC by two pathologists from the China-Japan Friendship Hospital. If there was a difference in opinion, the slides were discussed until a consensus was reached. The slides were assessed according to the novel IASLC/ATS/ERS classification ([@b4-ol-0-0-4154]). The tumors were graded according to a three-tier grading system as follows: Low-grade, including ADC *in situ* (AIS), minimally invasive ADC (MIA) and the lepidic pattern of invasive ADC; intermediate-grade, including papillary and acinar patterns; and high-grade, including micropapillary, solid patterns and variants of invasive ADC ([@b5-ol-0-0-4154],[@b15-ol-0-0-4154]). Finally, the histopathological scores of the patients were calculated by adding the two most predominant grades observed for each patient ([@b15-ol-0-0-4154]). Tumors composed of a pure histological subtype were scored by double tumor grading.

The following histopathological characteristics were also investigated: Tumor size, which was defined as the maximum tumor diameter; pathological stage according to 2010 American Joint Committee for Cancer tumor-node-metastasis (TNM) staging manual ([@b16-ol-0-0-4154]); and lymphovascular invasion (LVI), tumor cells that were observed in the lymphatic and vascular lumen.

### Detection of EGFR mutations

EGFR mutations were detected by the amplification refractory mutation system (ARMS), as previously described ([@b17-ol-0-0-4154]). ARMS analysis was conducted using an AmoyDx® EGFR Mutations Test kit (Amoyx Diagnostics, Co., Ltd., Xiamen, China), which has received China Food and Drug Administration approval for clinical use in mainland China. The EGFR mutations kit covered 29 EGFR mutation hotspots between exons 18 and 21. The assay was performed according to the manufacturer\'s protocols, with the Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The end result for the analysis was positive or negative, which was determined using the criteria that was defined by the manufacturer\'s protocol. Briefly, DNA was extracted from 2--20 mg tumor tissue. The DNeasy Tissue Kit (Qiagen, Hilden, Germany) was used to extract DNA according to the manufacturer\'s protocol. The concentration and purity of DNA were determined by the NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Inc.). DNA extracted from the tumor tissue was standardized to 1 ng/µl. All reactions were performed in 25 µl volumes, including 4.7 µl of template DNA, 0.3 µl of Taq polymerase and 20 µl of reaction buffer mix, and all primers and reagents were included in the AmoyDx® EGFR Mutations Test kit. PCR thermal cycling was as follows: 5 min incubation at 95°C, followed by 15 cycles of 95°C for 25 sec, 64°C for 20 sec and 72°C for 20 sec, and then 31 cycles of 93°C for 25 sec, 60°C for 35 sec and 72°C for 20 sec. Fluorescent signal was collected from the FAM and HEX channels. Data analysis was performed with MxPro version 4.10 (Stratagene, La Jolla, CA, USA). The cycle threshold (Cq) accounts for the threshold at which the signal was detected above background fluorescence. Normal human genomic DNA was used as a control. ΔCq values were calculated as the difference between the mutation Cq and control Cq ([@b18-ol-0-0-4154]). Positive results were deﬁned as follows: i) Cq is \<26; ii) Cq is \>26 and ΔCq is lower compared with the cut-off ΔCq value (11 for 19Del and L858R, 7 for T790M). The analysis of each sample was performed in duplicate and the entire test process required 90 min.

### Statistical analysis

Continuous variables were examined for normality and skewness. Non-normally distributed data were expressed as the median and interquartile range. The χ^2^ test and Fisher\'s exact test were used to compare categorical variables between groups. Mann-Whitney and Kruskal-Wallis tests were used to compare the non-normally distributed variables between groups. Univariate and multivariate logistic regression analyses were performed to investigate the association between clinical characteristics and EGFR mutations. SPSS version 20.0 software (IBM SPSS, Armonk, NY, USA) was used for all statistical analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

The clinicopathological characteristics of the 97 patients with lung ADC are summarized in [Table I](#tI-ol-0-0-4154){ref-type="table"}. The patient cohort consisted of 50 men (51.5%) and 47 women (48.5%). The median age of the patients was 66 years (range, 34--86 years). The pathological TNM stages of the patients were as follows: Stage I, 58 patients; stage II, 15 patients; and stage III, 24 patients. The range of the SUVmax of the primary tumors was 0.9--31.0, with a median of 4.4 \[interquartile range (IQR), 3.1--12.4\] ([Fig. 1](#f1-ol-0-0-4154){ref-type="fig"}). EGFR mutations were identified in 44 out of the 97 patients (45.4%). The patients identified had mutations in exon 19 in 21 patients (47.7%) and in exon 21 in 23 patients (52.3%).

### Lung ADC histopathological subtypes and histopathological scores

The histopathological subtypes of lung ADC, identified according to the IASLC/ATS/ERS classification, were AIS in 2 patients (2.1%), MIA in 3 patients (3.1%), lepidic predominant in 14 patients (14.4%), acinar predominant in 28 patients (28.9%), papillary predominant in 38 patients (39.2%), solid predominant in 9 patients (9.3%), micropapillary predominant in 2 patients (2.1%) and variants of invasive ADC in 1 patient (1.0%). In total, 77 patients (79.4%) were classified as a mixed subtype according to the 2004 WHO classification. The histopathological scores were calculated and are shown in [Table I](#tI-ol-0-0-4154){ref-type="table"}.

### Association between EGFR mutations and clinicopathological characteristics

The association between the EGFR mutations and clinicopathological characteristics of the patients were evaluated using univariate analysis ([Table I](#tI-ol-0-0-4154){ref-type="table"}). EGFR mutations were more frequently identified in women compared with men (57.4 vs. 34.0%; P=0.020) and in non-smokers compared with former or current smokers (63.0 vs. 29.4%; P=0.001). Patients with mutant EGFR in their primary tumors possessed a lower histopathological score compared with patients with wild-type EGFR (P=0.002). Patients with mutant EGFR possessed significantly lower SUVmax compared with patients with wild-type EGFR (P=0.034; [Fig. 2](#f2-ol-0-0-4154){ref-type="fig"}). The pathological stage of the patients was associated with EGFR mutations (P=0.034). Age and serum CEA level of the patients, tumor location, tumor size, pathological T factor, pathological N factor and LVI demonstrated no significant associations with the frequency of EGFR mutations.

Variables with P\<0.05 in the univariate analysis were investigated with a logistic regression model. In the univariate logistic regression analysis, the gender, smoking history and histopathological score of the patients were significantly associated with the presence of EGFR mutations (P=0.022, P=0.001 and P=0.004, respectively). To eliminate the potential confounding effect, multivariate logistic regression analysis was used to identify independent factors for EGFR mutations. The present results demonstrated that smoking history (OR, 0.287; P=0.030) and histopathological score (OR, 0.508; P=0.027) were independent factors associated with the presence of EGFR mutations ([Table II](#tII-ol-0-0-4154){ref-type="table"}). The present results indicated that gender and SUVmax were confounding factors for EGFR mutations.

### Comparison of characteristics between patients stratified by histopathological score

Patients were stratified into the following groups according to their histopathological score: Low-score, 2 or 3 points (40 patients); intermediate-score, 4 points (40 patients); and high-score, 5 or 6 points (17 patients). The association between SUVmax, LVI, EGFR mutation status and the histopathological patient groups are summarized in [Table III](#tIII-ol-0-0-4154){ref-type="table"}. The high-score group had the highest SUVmax (median, 11.7; IQR, 4.9--15.1), followed by the intermediate-score (median, 4.8; IQR, 3.5--12.7) and low-score (median, 3.4; IQR, 1.9--5.7) groups ([Fig. 3](#f3-ol-0-0-4154){ref-type="fig"}). A high histopathological score was associated with a higher probability of LVI (P=0.008). By contrast, the incidence of EGFR mutations appeared to be significantly decreased when associated with a higher histopathological score (P=0.005; [Fig. 4](#f4-ol-0-0-4154){ref-type="fig"}). Furthermore, when the patients were stratified by smoking history and histopathological score, the incidence of EGFR mutations was highest in non-smokers from the low-score group, and the incidence of EGFR mutations was extremely low in smokers of the intermediate- and high-score groups ([Fig. 5](#f5-ol-0-0-4154){ref-type="fig"}).

Discussion
==========

The present study performed an extensive analysis based on several previously described associations in lung ADC between clinicopathological patient characteristics, histopathological subtypes and EGFR mutations ([@b11-ol-0-0-4154]--[@b13-ol-0-0-4154]). Histopathological subtypes, diagnosed according to IASLC/ATS/ERS classification, were observed to be associated with SUVmax and EGFR mutations in lung ADC. The tumors of patients with higher histopathological scores were more likely to have a higher SUVmax and wild-type EGFR status. Therefore, the present study hypothesized that the IASLC/ATS/ERS classification reflects not only morphological heterogeneities, but also functional characteristics and genetic alterations. The present findings would be beneficial for determining therapeutic strategies for patients with lung ADC.

Previous studies have revealed that EGFR mutations are predominantly identified in Asian populations, women, individuals that have never smoked and ADC patients ([@b19-ol-0-0-4154]--[@b21-ol-0-0-4154]). In the current study, the frequency of EGFR mutations was 45.7%, and a high frequency of these EGFR mutations was associated with women, patients that had never smoked and a lower SUVmax and histopathological score. Furthermore, the present study revealed that the smoking history and histopathological score of the patients were independent factors for the presence of EGFR mutations, following the adjustment for confounding variables using multivariate analysis. Similar results have been reported in a study by Hsiao *et al* ([@b22-ol-0-0-4154]), which found that gender was a confounding factor, whereas the smoking history and histological subtype of patients were independently and significantly associated with EGFR mutations in non-small cell lung cancer.

In addition, the present study demonstrated that there was an association between EGFR mutations and the histopathological score of the patients. EGFR mutations occurred more frequently in patients with lower histopathological scores. Several studies have investigated the association between EGFR mutations and the IASLC/ATS/ERS classification; however, the results remain inconsistent, as summarized in [Table IV](#tIV-ol-0-0-4154){ref-type="table"} ([@b12-ol-0-0-4154],[@b13-ol-0-0-4154],[@b23-ol-0-0-4154]--[@b31-ol-0-0-4154]). The variations between EGFR mutations and histological subtypes in these previous results may be due to the cohort size, molecular analytical methods employed and ethnicity of the study cohort. Notably, smoking history, which the present study demonstrated is an independent predictor for the presence of EGFR mutations, may possibly contribute to inconsistent results. The dose of tobacco smoke exposure is hypothesized to be inversely associated with the rate of EGFR mutations ([@b32-ol-0-0-4154],[@b33-ol-0-0-4154]). In addition, the majority of ADCs have various combinations of two or more histological subtypes. Therefore, evaluating the association between EGFR mutations and histology according to the most predominant histological subtype may not be accurate.

Despite the controversial results, ADCs with lower-grade predominant subtypes generally have a higher frequency of EGFR mutations ([@b23-ol-0-0-4154]--[@b31-ol-0-0-4154]). The mechanism for the association between EGFR mutations and histological subtypes remains unclear. It has been hypothesized that the origin of the majority of lung ADCs are type 2 pneumocytes, Clara cells and precursor cells, which are common in the terminal respiratory unit. The activation of the EGFR signaling pathway, including the activation of downstream mediators, is an early and essential event for ADC oncogenesis ([@b34-ol-0-0-4154],[@b35-ol-0-0-4154]); however, the EGFR pathway plays a decreased role in developed lung cancer. Additionally, Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, which are associated with a solid growth pattern, usually occur in a mutually-exclusive manner with EGFR mutations. Therefore, EGFR mutations are less frequent in the solid predominant subtype of lung ADC ([@b36-ol-0-0-4154],[@b37-ol-0-0-4154]).

The present study revealed that there is an association between the SUVmax and the histopathological score of patients. Lung ADC with a lepidic subtype is well known to possess a lower SUVmax compared with lung ADC without a lepidic subtype ([@b38-ol-0-0-4154]). Chiu *et al* ([@b11-ol-0-0-4154]) demonstrated that the SUVmax was significantly higher in solid predominant ADC compared with ADC with other predominant histology. In addition, Kadota *et al* ([@b39-ol-0-0-4154]) observed that tumors with high-grade histology exhibited the highest SUVmax \[mean ± standard deviation (SD), 6.2±2.8\], followed by those with intermediate-grade (3.7±2.5) and low-grade (2.5±1.6) histology. ^18^F-FDG uptake reflects the proliferation and aggressiveness of lung cancer cells, which may explain why the SUVmax varies dramatically depending on histological components ([@b40-ol-0-0-4154]). AIS, MIA and lepidic growth patterns of ADC, which often present with ground-glass opacity lesions, have a much longer tumor volume doubling time compared with semi-solid and solid lesions, and the SUVmax is associated with the tumor volume doubling time and proliferation rate ([@b41-ol-0-0-4154]--[@b43-ol-0-0-4154]). Consequently, the SUVmax is lower in tumors that possess a lower histopathological score.

Since the SUVmax and EGFR mutations are closely associated with the histopathological score, the SUVmax is more likely to be associated with EGFR mutations. Usuda *et al* ([@b44-ol-0-0-4154]) reported that tumors with a mutant EGFR status possessed a significantly lower SUVmax (mean ± SD, 3.66±4.53) compared with tumors with a wild-type EGFR status (8.26±6.11; P\<0.0001). In addition, Na *et al* ([@b45-ol-0-0-4154]) demonstrated that patients with a low SUVmax were more likely to possess EGFR mutations compared with patients with a high SUVmax (low vs. high SUVmax, 40 vs. 11%; P=0.001). Mak *et al* ([@b46-ol-0-0-4154]) also reported that a high SUVmax was associated with wild-type EGFR. In the present study, tumors with mutant EGFR exhibited a significantly lower SUVmax, which is consistent with previous studies. In terms of the molecular mechanism underlying the association between SUVmax and EGFR mutation, the SUVmax is significantly associated with the expression of glucose transporter-1 (GLUT-1) in lung cancer, and overexpressed GLUT-1 is indicative of the increasing proliferative activity, energy requirements and aggressive behavior of cells ([@b47-ol-0-0-4154]--[@b49-ol-0-0-4154]). Yun *et al* ([@b50-ol-0-0-4154]) observed that an increase in GLUT-1 expression and glucose uptake was critically dependent on KRAS mutations in colorectal cancer cells, and Sasaki *et al* ([@b51-ol-0-0-4154]) identified that GLUT-1 overexpression was significantly associated with the gene mutation status of tumors, including EGFR (mutant vs. wild-type, 23.4 vs. 58.3%; P\<0.0001) and KRAS (mutant vs. wild-type, 66.7 vs. 46.6%; P=0.038). These results support the fact that the SUVmax is decreased in tumors that possess mutant EGFR compared with tumors with wild-type EGFR.

The present results have potential practical implications. Firstly, although the IASLC/ATS/ERS classification and EGFR mutation status are important factors for determining therapeutic strategies for patients, they are occasionally not feasible due to the inoperability of the patients, insufficient tissue materials available or the high cost of the molecular examination. Since pre-operative SUVmax is possibly a predictor for the aggressiveness and EGFR mutation status of ADC, the present study identified patients who were at a high-risk of post-operative tumor relapse and patients who were sensitive to EGFR-targeted therapy without examining a surgical tumor specimen. Patients with a high SUVmax should be considered for intensive treatment in order to reduce recurrence and improve survival outcomes, including anatomical pulmonary resection instead of limited resection, and may not benefit from EGFR-targeted therapy. Secondly, the smoking history combined with the histopathological score of patients provides a potential predictor for EGFR mutations, which would be useful if molecular examination is not available.

The present study concludes that the smoking history and histopathological score of patients with lung ADC, based on the two most predominant subtypes of lung ADC, are independent factors associated with the EGFR mutation status. Lung ADCs of various histopathological subtypes vary in terms of metabolic activity and EGFR mutations. The present results support the fact that the histopathological score is a powerful tool for stratifying patients with lung ADC according to the biological aggressiveness and molecular alteration of tumors. However, as a retrospective and single-center study, there was inevitably patient selection bias, and there was a relatively small number of patients with a histopathological score of 2 or 6. Additional in-depth analyses may benefit the validation of the association between these radiographical, histopathological and molecular characteristics, which may provide a promising strategy for patient care.

The present study was supported by grants from the National Key Clinical Specialty Construction Program of China (grant no. 2011873).
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![Distribution of SUVmax in patients with wild-type or mutated EGFR status. Patients with mutated EGFR have a significantly lower SUVmax compared with patients with wild-type EGFR (P=0.018). Open circle represents mild outliers, asterisk represents extreme outliers. SUVmax, maximum standardized uptake value; EGFR, epidermal growth factor receptor.](ol-11-03-1769-g01){#f2-ol-0-0-4154}

![SUVmax in patients with lung adenocarcinoma stratified according to the histopathological score (P\<0.001). The high-score group of patients has the highest SUVmax, followed by the intermediate-score group and the low-score group. Open circle represents mild outliers, asterisk represents extreme outliers. SUVmax, maximal standardized uptake value.](ol-11-03-1769-g02){#f3-ol-0-0-4154}

![Frequency of mutated and wild-type EGFR in patients with lung adenocarcinoma stratified according to histopathological score (P=0.005). The low-score group has the highest incidence of EGFR mutations, followed by the intermediate- and high-score groups. EGFR, epidermal growth factor receptor.](ol-11-03-1769-g03){#f4-ol-0-0-4154}

![Frequency of mutated EGFR in patients with lung adenocarcinoma stratified according to histopathological score and smoking status. The incidence of EGFR mutations was highest in patients who were non-smokers and were of the histopathological low-score group, while the incidence of EGFR mutations was extremely low in smokers of the intermediate- and high-score groups of patients. EGFR, epidermal growth factor receptor.](ol-11-03-1769-g04){#f5-ol-0-0-4154}

###### 

Association between the clinicopathological characteristics of 97 patients with lung adenocarcinoma and EGFR mutations in the tumors of these patients.

  Characteristic                   Patients, n (%)   Wild-type EGFR        Mutated EGFR          P-value
  -------------------------------- ----------------- --------------------- --------------------- ---------
  Total, n (%)                     97 (100.0)        53 (54.6)             44 (45.4)             
  Gender, n (%)                                                                                  0.020
    Male                           50 (51.5)         33 (66.0)             17 (34.0)             
    Female                         47 (48.5)         20 (42.6)             27 (57.4)             
  Age, n (%)                                                                                     0.461
    \<65 years                     38 (39.2)         19 (50.0)             19 (50.0)             
    ≥65 years                      59 (60.8)         34 (57.6)             25 (42.4)             
  Smoking status, n (%)                                                                          0.001
    No                             46 (47.4)         17 (37.0)             29 (63.0)             
    Yes                            51 (52.6)         36 (70.6)             15 (29.4)             
  CEA level, n (%)                                                                               0.176
    \<5 ng/ml                      50 (51.5)         24 (48.0)             26 (52.0)             
    ≥5 ng/ml                       47 (48.5)         29 (61.7)             18 (38.3)             
  Tumor site, n (%)                                                                              0.199
    Left upper lobe                21 (21.6)         12 (57.1)               9 (42.9)            
    Left lower lobe                13 (13.4)           6 (46.2)              7 (53.8)            
    Right upper lobe               34 (35.1)         23 (67.6)             11 (32.4)             
    Right middle lobe                8 (8.2)           2 (25.0)              6 (75.0)            
    Right lower lobe               21 (21.6)         10 (47.6)             11 (52.4)             
  TNM stage, n (%)                                                                               0.034
    I                              58 (59.8)         32 (55.2)             26 (44.8)             
    II                             15 (15.5)         12 (80.0)               3 (20.0)            
    III                            24 (24.7)           9 (37.5)            15 (62.5)             
  T factor, n (%)                                                                                0.270
    1                              36 (37.1)         16 (44.4)             20 (55.6)             
    2                              49 (50.5)         29 (59.2)             20 (40.8)             
    3                              12 (12.4)           8 (66.7)              4 (33.3)            
  N factor, n (%)                                                                                0.231
    0                              64 (66.0)         38 (59.4)             26 (40.6)             
    1                              10 (10.3)           6 (60.0)              4 (40.0)            
    2                              23 (23.7)           9 (39.1)            14 (60.9)             
  LVI, n (%)                                                                                     0.469
    Negative                       48 (49.5)         28 (58.3)             20 (41.7)             
    Positive                       49 (50.5)         25 (51.0)             24 (49.0)             
  Histopathological score, n (%)                                                                 0.002
    2                              3 (3.1)             1 (33.3)              2 (66.7)            
    3                              37 (38.1)         13 (35.1)             24 (64.9)             
    4                              39 (40.2)         26 (66.7)             13 (33.3)             
    5                              10 (10.3)           6 (60.0)              4 (40.0)            
    6                                8 (8.2)           7 (87.5)              0 (0.0)             
  Tumor size median (IQR), mm                          25.0 (18.0--40.0)     24.0 (16.5--34.8)   0.334
  SUVmax median (IQR)                                  5.7 (3.6--12.8)       3.8 (2.5--8.9)      0.034

EGFR, epidermal growth factor receptor; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis; LVI, lymphovascular invasion; SUVmax, maximum standardized uptake value; IQR, interquartile range.

###### 

Logistic regression analysis of clinicopathological characteristics of patients with lung adenocarcinoma as predictors of epidermal growth factor receptor mutations.

                                   Univariate analysis   Multivariable analysis                                  
  -------------------------------- --------------------- ------------------------ ------- ------- -------------- -------
  Gender (male vs. female)         0.382                 0.168--0.869             0.022   1.142   0.355--3.667   0.824
  Smoking history (yes vs. no)     0.244                 0.104--0.571             0.001   0.287   0.093--0.884   0.030
  Histopathological score          0.472                 0.284--0.785             0.004   0.508   0.278--0.928   0.027
  SUVmax                           0.943                 0.881--1.010             0.092   0.973   0.893--1.061   0.538
  Tumor stage (II and III vs. I)   1.290                 0.805--2.067             0.290   1.552   0.864--2.788   0.141

Histopathological score and SUVmax were treated as continous variables. OR, odds ratio; CI, confidence interval; SUVmax, maximum standardized uptake value.

###### 

Association between 97 patients with lung adenocarcinoma stratified according to histopathological score and the SUVmax, LVI and EGFR mutation status of these patients.

                  Hisbottomathological score, n (%)                            
  --------------- ----------------------------------- ----------- ------------ -------
  SUVmax                                                                       0.005
    \<4.4         27 (67.5)                           17 (42.5)     4 (23.5)   
    ≥4.4          13 (32.5)                           23 (57.5)   13 (76.5)    
  LVI                                                                          0.008
    Negative      25 (62.5)                           20 (50.0)     3 (17.6)   
    Positive      15 (37.5)                           20 (50.0)   14 (82.4)    
  EGFR mutation                                                                0.005
    Negative      14 (35.0)                           27 (67.5)   12 (70.6)    
    Positive      26 (65.0)                           13 (32.5)     5 (29.4)   

SUVmax, maximum standardized uptake value; LVI, lymphovascular invasion; EGFR, epidermal growth factor receptor.

###### 

Previous studies of correlation between EGFR mutation and predominant subtype.

  First author, year        Patients, n   Freq. EGFR mutations, %   Freq. distribution EGFR mutations in various predominant tumor subtypes, %                                                                                               Ref.
  ------------------------- ------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------
  Shim *et al*, 2011        107           50.5                      Micropapillary (83.3) \> lepidic (62.5) \> acinar (50.0) = papillary (50.0) \> solid (28.6)                                                                              ([@b23-ol-0-0-4154])
  Sun *et al*, 2012         382           51.3                      Papillary (70.0) \> acinar (56.6) \> micropapillary (50.0) \> lepidic (42.9) \> solid (38.9)                                                                             ([@b24-ol-0-0-4154])
  Zhang *et al*, 2012       349           76.2                      AIS (100.0) = MIA (100.0) \> micropapillary (83.3) \> acinar (83.1) \> lepidic (82.4) \> papillary (72.2) \> solid (60.9) \> invasive mucinous adenocarcinoma (28.6)     ([@b25-ol-0-0-4154])
  Russell *et al*, 2013     59            29.0                      Acinar (44.0) \> micropapillary (38.0) \> solid (5.0) \> papillary (0.0)                                                                                                 ([@b26-ol-0-0-4154])
  Song *et al*, 2013        161           41.6                      Micropapillary (73.9) \> lepidic \> (72.2) \> acinar (42.1) \> papillary (40.5) \> MIA (16.7) = solid (16.7) \> variants of invasive adenocarcinoma (0.0)                ([@b27-ol-0-0-4154])
  Yoshizawa *et al*, 2013   167           53.9                      AIS (85.7) \> MIA (83.3) \> lepidic (71.4) \> papillary (68.5) \> micropapillary (40.1%) \> acinar (38.4%) \> solid (14.3 %) \> invasive mucinous adenocarcinoma (0.0)   ([@b12-ol-0-0-4154])
  Tsuta *et al*, 2013       880           40.5                      Papillary (56.0) \> lepidic (44.6) \> micropapillary (39.7) \>AIS + MIA (39.0) \> acinar (32.3)\> solid (15.8) \> invasive mucinous predominant (0.0)                    ([@b28-ol-0-0-4154])
  Yanagawa *et al*, 2014    131           54.4                      Lepidic (77.0) \> AIS (62.0) \> MIA (60.0) \> papillary (50.0) \> acinar (49.0) \> micropapillary (43.0) \> solid (28.0) \> invasive mucinous adenocarcinoma (0.0)       ([@b13-ol-0-0-4154])
  Villa *et al*, 2014       200           20.5                      Lepidic (44.0) \> acinar (42.0) \> solid (10.0) \> papillary (5.0) \> micropapillary (0.0)                                                                               ([@b29-ol-0-0-4154])
  Sun *et al*, 2014         102           38.2                      Micropapillary (70.6) \> lepidic (50.0) \> papillary (33.3) \> acinar (30.0) \> solid (8.3) \> variants of invasive adenocarcinoma (0.0)                                 ([@b30-ol-0-0-4154])
  Kim *et al*, 2014         135           37.6                      Papillary (81.3)\> lepidic (70.4)\> acinar (58.1) \> solid (28.3)                                                                                                        ([@b31-ol-0-0-4154])

EGFR, epidermal growth factor receptor; freq., frequency; ref., reference; AIS, adenocarcinoma *in situ*; MIA, minimally invasive adenocarcinoma.
